Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05827471

Clinical Study of QSOX1 as a Biomarker for Colon Cancer

The goal of this observational study is to determine whether the secreted protein QSOX1 can be used as a molecular marker for early rapid diagnosis and accurate treatment of colon cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Colon Cancer Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

About this study

The project mainly selects the tumor group represented by colon cancer and the corresponding healthy people as the control group, with about 100 cases in each of the two groups. Mainly collect blood and tumor tissue samples of patients, detect the expression of QSOX1 in the above samples, and explore the role in the diagnosis and prognosis evaluation of colon cancer.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Colon cancer was confirmed by colonoscopic pathology.
  • No local or systemic treatment was performed before operation.
  • Complete clinical data.

Exclusion criteria

  • Combined with benign diseases of colon, such as ulcerative colitis, colon adenoma and colon polyp.
  • Other tumors other than colon cancer.

Treatment and study plan

Diagnosis of colon cancer

Diagnostic Test

Clinical diagnosis results

Primary outcomes

  1. Detection of RNA for early rapid diagnosis of colon cancer.

    Time frame: 6 months

    RT-PCR was used to detect the RNA levels of QSOX1 in the tumor and control groups.

  2. Detection of protein for early rapid diagnosis of colon cancer.

    Time frame: 6 months

    Western blotting was used to detect the protein levels of QSOX1 in the tumor and control groups.

Sponsors and collaborators

Lead sponsor

Qianfoshan Hospital

Other

Registry information

Official study title

Clinical Application of Sulfhydryl Oxidase QSOX1 as a New Biomarker of Colon Cancer

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Apr 25, 2023
Registry last updated
Apr 25, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.